Results 161 to 170 of about 36,908,348 (344)

Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence ‐ Traduction française [PDF]

, 2012
OCEBM Levels of Evidence Working Group,
core  

Association of reactive oxygen species levels and radioresistance in cancer stem cells

Nature, 2009
M. Diehn, Robert W. Cho, N. Lobo, T. Kalisky, M. Dorie, A. Kulp, Dalong Qian, Jessica S. Lam, Laurie E. Ailles, Manzhi Wong, Benzion Joshua, M. J. Kaplan, I. Wapnir, F. Dirbas, G. Somlo, C. Garberoglio, B. Paz, Jeannie Shen, S. Lau, Stephen R. Quake, J. Brown, I. L. Weissman, Michael F. Clarke   +22 more
semanticscholar   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Time-dependent integrated tissue and circulating biomarker dynamics of spexin and progranulin in an experimental myocardial infarction model. [PDF]

Histochem Cell Biol
Kaya S, Yalçin T.
europepmc   +1 more source

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.

New England Journal of Medicine, 2002
D. Cummings, D. Weigle, R. S. Frayo, P. Breen, Marina K. Ma, E. Dellinger, J. Purnell   +6 more
semanticscholar   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Levels of care for maternal and neonatal healthcare: a scoping review. [PDF]

J Glob Health
Mackin S, Day LT, Dekker C, Gouse I, Maina M, Aluvaala J, Moran A, Revisioning Emergency Obstetric and Newborn Care (EmONC) levels-of-care workstream.   +7 more
europepmc   +1 more source

Temperature Level [PDF]

BMJ, 1965
openaire   +2 more sources

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Role of insulin-regulated aminopeptidase as potential biomarker in insulin resistant polycystic ovary syndrome patients. [PDF]

Arch Endocrinol Metab
Köse O, Gök K, Köse E, Gözükara SI, Tüten A, Bostancı MS.   +5 more
europepmc   +1 more source